Aug 05, 2021 11:45 JST

Source: Eisai

Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards

TOKYO, Aug 05, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo).

The Corporate Communications Awards were established in 1984 with the aim of advancing the field by recognizing companies and individuals that practice excellent corporate communications. There are three awards: the Award for Excellence in Corporate Communications, Outstanding Leadership Awards in Corporate Communications, and the Outstanding Merit Awards.

The Award for Excellence in Corporate Communications received by Eisai is given to the company that contribute to society by identifying what is expected and required of them by society, reflecting this in their management, and disseminating and communicating accurate information about their corporate activities to their stakeholders through public relations initiatives.

The award was presented to Eisai in recognition of its efforts to promote understanding of dementia, which has become a social issue, by providing not only information on the status of new drug development, but also on the latest findings on the pathological condition of the disease and the social burden of nursing care, as well as efforts to promote understanding among stakeholders through study sessions for scientific and medical journalists and providing easy-to-understand explanations of difficult science, thereby making a significant contribution to increase the benefits of patients and their families in line with its corporate philosophy of human health care (hhc).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In the new medium-term business plan "EWAY Future & Beyond" started in FY2021, based on the hhc philosophy, Eisai aims to remove the anxiety of "The People", including not only patients but also society at large, by delivering not only pharmaceutical products but also solutions to The People. In order to realize the hhc philosophy, we will make further contributions to increase the benefits to "The People" by enhancing corporate value through public relations activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
October 18 2021 08:00 JST
 
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
September 28 2021 10:37 JST
 
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
September 27 2021 13:50 JST
 
Eisai to Join The Global Environmental Initiative "RE100"
September 14 2021 16:46 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
September 14 2021 11:36 JST
 
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
September 13 2021 15:37 JST
 
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
August 31 2021 08:42 JST
 
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
August 16 2021 09:07 JST
 
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
August 12 2021 08:31 JST
 
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
August 02 2021 11:24 JST
 
More Press release >>

Latest Press Release


More Latest Release >>